January 28th 2021, 10:00pm
Biomarkers play an important role in treatment decisions of many tumors, but in lung cancer they are a deciding factor between which immunotherapy is the best option.
January 2nd 2021, 3:00pm
In an interview with CURE®, Dr. Wade T. Iams discussed small cell lung cancer, a subtype of lung cancer that starts from neuroendocrine cells in the lung, how different stages are treated and the potential benefits of having a treatment team to communicate with every step of the way.
December 22nd 2020, 7:00pm
Dr. Sally J. York goes over the types of immunotherapy-related side effects, and what patients with lung cancer and their caregivers should look out for.
December 16th 2020, 7:00pm
View all three sessions of the CURE Educated Patient Lung Cancer Summit here!
First Patients Dosed in Three Trials Assessing Dato-DXd-Based Regimens in Lung Cancer
Opdivo and Yervoy May Improve Survival for Resected Stage 3/4 Melanoma
A Month Without Pink, Almost
Inrebic May Reduce Spleen Volume in Myelofibrosis